NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics, Inc. (
NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences:
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on OutlookOncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.6% year on year to $190.2 million. The company expects the full year’s revenue to be around $797 million, close to analysts’ estimates. Its non-GAAP profit of $0.06 per share was $0.02 above analysts’ consensus estimates.
NeoGenomics’s (NASDAQ:NEO) Q4 CY2025 Sales Beat EstimatesOncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.6% year on year to $190.2 million. The company expects the full year’s revenue to be around $797 million, close to analysts’ estimates. Its non-GAAP profit of $0.06 per share was $0.02 above analysts’ consensus estimates.
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its fourth-quarter and full-year results for the period ended December 31, 2025.
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look ForOncology (cancer) diagnostics company NeoGenomics (
NASDAQ:NEO)
will be announcing earnings results this Tuesday before the bell. Here’s what investors should know.
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
NeoGenomics, Inc. (
NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the availability of PanTracer Pro, a new addition to the PanTracer® Family, designed to help clinicians navigate increasingly complex molecular testing workflows to make informed decisions for patients with advanced-stage solid tumors.
1 Stock Under $50 Worth Your Attention and 2 We Brush OffStocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
NeoGenomics, Inc. (
NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.
3 Cash-Burning Stocks with Warning SignsRapid spending isn’t always a sign of progress.
Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
NeoGenomics, Inc. (
NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company’s Chief Financial Officer.
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
NeoGenomics, Inc. (
NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
NeoGenomics, Inc. (
NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. “Jack” Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service.
3 Russell 2000 Stocks We Think Twice AboutSmall-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names.
But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
3 Stocks Under $50 We Steer Clear OfThe $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
NeoGenomics, Inc. (
NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its cross-appeal) of the North Carolina District Court’s August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics’ favor.
NeoGenomics to Present New ctDNA Research at SABCS 2025
NeoGenomics, Inc. (
NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that data utilizing its RaDaR® 1.0 assay for the detection of molecular residual disease (MRD) will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
NeoGenomics, Inc. (
NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and guide treatment decisions for patients with myeloid malignancies at the 67th American Society of Hematology (ASH) Annual Meeting, which is being held Dec. 6–9, 2025, in Orlando, Florida.
Testing & Diagnostics Services Stocks Q3 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how NeoGenomics (
NASDAQ:NEO) and the rest of the testing & diagnostics services stocks fared in Q3.
3 Overrated Stocks That Concern UsThe stocks featured in this article are seeing some big returns.
Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
1 Cash-Burning Stock to Research Further and 2 We Brush OffRapid spending isn’t always a sign of progress.
Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
NeoGenomics, Fortrea, and Acadia Healthcare Shares Skyrocket, What You Need To KnowA number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
1 High-Flying Stock on Our Buy List and 2 We Find RiskyExpensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match.
The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.
